Lilly Adds To Diabetes Pipeline With Protomer Buyout

 
• By Joseph Haas
  
Insulin ampoule and a syringe isolated against white background
With its buyout of Protomer, Lilly hopes it can develop a safer, more efficacious insulin
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business